TET2 mutations are loss of function mutations and have been implicated in the pathogenesis of AITL and TFH derived PTCL (70-80% of cases), ALK- negative ALCL (33% of cases). The gene discussed is TET2; the disease is angioimmunoblastic T-cell lymphoma.